Cambridge, Massachusetts, USA
RevolKa developed a proprietary technology to explore the vast sequence space, called aiProtein®. This is achieved by integrating directed protein evolution with artificial intelligence (AI). RevolKa is committed to quality biological data with less noise and errors, which accurately trains our machine-learning engines. aiProtein® does not require big data, but relatively smaller numbers of data for accurate prediction. This saves time and labor significantly, and opens opportunities for complex biological data, such as cell cytotoxicity and receptor internalization. aiProtein® has been highly validated with different types of proteins, such as antibodies and enzymes.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for RevolKa on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
